The MedImmune-backed glaucoma treatment developer aims to raise up to $86.3m from its initial public offering, as well as an additional $46m in convertible debt.

AbbbVie-backed Virobay had planned to raise up to $50m in an initial public offering that would have funded development of its drug development programme.

Napo Pharmaceuticals-backed pet medicine developer Jaguar Animal Health is set to raise $40.4m if it floats at the middle of its range.

The Johnson & Johnson-backed small protein-based treatment developer raised $102m two weeks after initially suspending the initial public offering due to market conditions.

Novo is set to invest up to $16m as the Johnson & Johnson, Covidien and Mayo Clinic-backed company goes public.

The corporate-backed company, which is developing treatments for peanut and milk allergies, secured $92.6m after raising approximately $50m in venture funding.

The China-based solar power producer will float in the US after setting a range if between $10 and $12m for the offering.

The Amgen and Celgene-backed pharmaceutical company raised the cash after pulling in $72m in venture funding over two years.

The Fosun-backed snack food retailer is set to issue 90 million shares in a Chinese initial public offering, three years after raising $42m.